Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis).
EURneffy is the first needle-free adrenaline treatment option in the EU, offering a more convenient and accessible alternative for adults and children with severe allergies.
It represents the first novel adrenaline delivery method in more than three decades, according to Richard Lowenthal, co-founder, president and CEO of ARS Pharma.
ARS Pharma anticipates that EURneffy will be available to patients in certain European Union member states in the fourth quarter of 2024.
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Agios receives orphan drug designation for tebapivat in MDS
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Sun Pharma and Moebius Medical's MM-II receives Fast Track designation for osteoarthritis knee pain
Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806